|Description||AS605240 is a selective PI3Kgamma inhibitor, has been proved effective on several inflammatory diseases. Orally administration of AS605240 significantly prevented lung inflammation and reduced collagen deposition. AS605240 also inhibited augmented expression of TNF-alpha and IL-1beta induced by bleomycin instillation. AS605240 may be a useful in treating inflammation diseases. AS605240 may represent a promising novel agent for the future therapy of pulmonary fibrosis.|
|Synonyms||AS 605240; AS605240.|
PI-3065 is a novel potent and selective PI3K p110δ inhibitor with IC50 of 15 nM; exhibits > 100 fold selectivity against p110α, p110β, p110γ, DNA-PK and mTOR.
GDC-0326 is a selective PI3Kα (α-Isoform of Phosphoinositide 3-Kinase) inhibitor. GDC-0326 is highly selective over other kinases. It has low plasma CL in human...
ZSTK474 is a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, which strongly inhibits cancer cell proliferation. Phosphoinositide 3-kinase (PI3K) is a pote...
ETP-46321 is a potent and orally bioavailable PI3K α, δ inhibitor with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after o...
A selective class I PI3K inhibitor; it inhibits PI3K p110 isoforms, mTOC1 and also DNA-PK; a valuable tool compound
Taselisib, also known as GDC0032 or RG7606, is a selective, potent, orally bioavailable inhibitor of PI3Ka with a Ki = 0.2nM, and with reduced inhibitory activi...
MLN1117, also known as INK1117, is a PI3Kα inhibitor which could lead to the apoptosis and growth retardation of tumor cells expressed by PI3Kα. IC50: 15 nM.
NVP-BKM120 Hcl(BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM, respectively.
GSK-2269557 HCl salt
GSK-2269557 is a selective Phosphatidylinositol 3 kinase delta inhibitor originated by GlaxoSmithKline. GSK-2269557 is highly selective for PI3Kδ over the close...
TGR-1202 hydrochloride is the hydrochloride salt of TGR-1202.TGR-1202, also known as RP5264, is a highly specific, orally available, PI3Kdelta inhibitor which i...
Pilaralisib, also known as XL147, is a methylbenzenesulfonamide derivative that reversibly inhibits class I PI3Ks (IC50s = 39, 36, 23, and 383 nM for p110α, δ, ...
CNX-1351 is a selective covalent Inhibitor of PI3Kα. In an end point assay, CNX-1351 potently inhibited PI3Kα and was 20−400 times less potent against β, γ, an...
This active molecular is a selective PI3Kδ inhibitor. PI3Kδ is hyperactivated in B-cell malignancies and plays a vital role in the B-cell receptor pathway. AM-0...
CAL-130 is a potent and selective PI3K gamma and delta inhibitor with potential anticancer activity. Constitutive phosphoinositide 3-kinase (PI3K)/Akt activatio...
Inhibition of p110α alone by A66 treatment is sufficient to block insulin signalling to Akt/PKB in certain cell lines that harbor H1047R mutations in PIK3CA and...
AS605240 is a selective PI3Kgamma inhibitor, has been proved effective on several inflammatory diseases. Orally administration of AS605240 significantly prevent...
IPI-549, a dihydroisoquinolin derivative, has been found to be a phosphatidylinositol 3 kinase gamma inhibitor, could exhibit antineoplastic activity in solid t...
Vps34-PIK-III is a potent and selective inhibitor of the type 3 phosphatidylinositol 3-kinase (PI3K) vacuolar protein sorting 34 (Vps34) (IC50= 18 nM). Vps34-PI...
Idelalisib is a kinase inhibitor. In combination with rituximab, it was used for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).
1,3-Dicaffeoylquinic acid, a caffeoylquinic acid derivative found in artichoke, acts as an anti-hyperlipidemic agent and activates PI3K/Akt.